In summary, our study highlights the potential value of BRAF inhibitors in treating anemia, from their therapeutic effects observed in vitro to their efficacy in DBA animal models, offering promise for improving outcomes in patients with refractory anemia and related disorders (Fig. 8). Here, BRAF is linked to anemia.